Study of the Effects of a FDA Approved Drug on Alzheimer's Disease

What we are studying

The purpose of this research study is to determine if a drug called methylphenidate helps people with Alzheimer’s disease and apathy. Apathy is a lack of interest or concern for things that others find moving or exciting.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Participants will have possible or probable Alzheimer's disease
  • Clinically significant apathy for at least four weeks
  • Availability of primary caregiver who spends greater than ten hours a week with the participant and supervises his/her care to accompany them to study visits and to participate in the study

What is involved

  • 7 Visits
  • 3 Telephone visits
  • Ecgs
  • Questionnaires
  • Paper & pencil memory testing
  • Vital signs


Participants will be paid $40.00 for each completed visit, up to a total of $280.00.

Contact Information

Study Coordinator
Tim Collare
Principal Investigator
Suzanne Craft, PhD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.